-
Chronic kidney disease = chronic renal insufficiency = progressive kidney disease = nephropathy
progressive loss of renal function over several months to years
-
Criteria for CKD
1. Kidney damage for > 3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifest by either: a) pathological abnormalities b) markers of kidney damage, including abnormalities in the composition of the blood or urin, or abnormalities in imaging tests
2. GFR < 60 ml/min/1.73 m2 for > 3 months, with or without kidney damage
-
Susceptibility risk factors for CKD
- 1. older age
- 2. decreased kidney mass
- 3. low birth weight
- 4. family history of CKD
- 5. US ethnic minority status
- 6. low income or eduction
-
Initiation risk factors for CKD (causing direct damage to kidney)
- 1. diabetes mellitus
- 2. hyeprtension
- 3. glomerulonephritis
-
progression risk factors for CKD
- 1. proteinuria
- 2. poor glycemic cotnrol in diabetes
- 3. elevated blood pressure
- 4. smoking
- 5. hyperlipidemia
- 6. obesity
-
What is the main structural marker for kidney damage?
proteinuria
-
List the amounts of protein present in a urine dipstick test.
- Trace: 15-30 mg/dL
- 1+: 30-100 mg/dL
- 2+: 100-300 mg/dL
- 3+: 300-1000 mg/dL
- 4+: > 1000 mg/dL
-
What is the albumin:creatinine ratios for spot urin collection?
- Normal: <30
- Microalbuminuria: 30-299
- Clinical proteinuria or albuminuria: > 300
-
What things should be screened annually (at minimum) for high risk patients?
- Scr
- CrCl
- GFR
- BP
- Cholesterol
- Symptoms
- CBC
-
DESCRIPTION: Kidney damage with normal or increased GFR
GFR: > 90
SYMPTOMS: none
STAGE: 1 CKD
-
DESCRIPTION: kidney damage with mild decreased GFR
GFR: 60-89
SYMPTOMS: none
STAGE: 2
-
DESCRIPTION: moderate decreased GFR
GFR: 30-59
SYMPTOMS: generally asymptomatic, HTN, anemia
STAGE: 3
-
DESCRIPTION: severe decreased GFR
GFR: 15-29
SYMPTOMS: nocturia, fatigue, cold intolerance, anorexia, hyperphosphatemia, hypocalcemia, metabolic acidosis
STAGE: 4
-
DESCRIPTION: kidney failure
GFR: < 15 (or dialysis)
SYMPTOMS: malaise, lack of energy, pruritis, N/V, myoclonus, asterixis, seizures
STAGE: 5
-
What are the desired outcomes of modifying the progression of renal disease?
- 1. Reverse or delay progression of renal injury
- 2. Reduce incidence of Stage 5 CKD
-
What is the nutritional management for modifying the progression of renal disease?
- 1. Dietary protein restriction
- 2. 0.6 g/kg/day of protein
- 3. Only for patients with GFR < 25 ml/min/1.73 m2
-
What are the 4 pharmacologic therapies for CKD?
- 1. Intensive glucose control - intensive insulin therapy (ITT)
- 2. Hypertension
- 3. Hyperlipidemia
- 4. Smoking cessation
-
What are the goals for intensive insulin therapy (ITT)?
- Preprandial goal: 70-130 mg/dL
- Postprandial goal: < 180 mg/dL
-
What are the goals for hypertension for CKD?
- Goal: < 130/80 mmHg
- Drugs of choice:
- a) Diabetes mellitus: ACE inhibitor or ARB
- b) Proteinuria: ACE inhibitor or ARB
- c) No diabetes, no proteinuria: Diuretic
-
What are the goals for hyperlipidemia for CKD?
- Goal LDL: < 100 mg/dL
- May limit progression of disease
-
What are the 3 main complications of decreased renal function?
- 1. decreased filtration, secretion, reabsorption
- 2. decreased endocrine function
- 3. decreased metabolic function
-
What occurs when there is decreased filtration, secretion, reabsorption?
- 1. build up of toxins
- 2. fluid & electrolyte disturbances
- 3. metabolic acidosis
-
What occurs when endocrine function is decreased due to a decrease in renal function?
Erythropoeitin is decreased causing anemia
-
What occurs when metabolic function is decreased due to a decrease in renal function?
Vitamin D decreases causing secondary hyperparathyroidism and renal osteodystrophy
-
Do people with CKD have an increased or decreased ability to concentrate or dilute urine?
Decreased
-
Fill in the blanks:
_____total renal Na excretion --> ___ body fluid --> volume _______
decreased total renal Na excretion --> increased body fluid --> volume overload
-
What is the goal serum Na for CKD?
between 135 and 145 without volume overload or depletion
-
What is the treatment for sodium and fluid balance for CKD?
- 1. No-added-salt diet
- 2. Fluids restriction
- a) not necessary if Na intake controlled
- b) reserve for dialysis patients between sessions
- 3. Diuretics
- a) loop diuretics
- b) loop + thiazide diuretics
-
What monitoring should be done for sodium and fluid balance for CKD patients?
blood pressure, volume status, and serum electrolytes (frequency depends on institution)
-
How is potassium homeostasis regulated?
Regulated by renal excretion, shifting in and out of cell, GI excretion
-
What happens to potassium homeostasis in stages 4 and 5 of CKD?
The body can no longer adapt to decreased renal excretion of potassium and hyperkalemia is unavoidable.
-
What are the goals for potassium homeostasis in CKD?
- 1. Prevent hyperkalemia and adverse consequences
- 2. Stage 2-3: maintain serum K in normal range (3.5-5)
- 3. Stage 4-5: maintain serum K between 4.5 and 6
-
What is the treatment for Acute hyperkalemia?
- 1. calcium gluconate
- 2. insulin (plus glucose)
- 3. beta-adrenergic agonists
- 4. sodium polystyrene sulfonate (kayexalate)
-
What is the treatment for Chronic hyperkalemia?
- 1. dietary restrictions
- 2. prevent constipation
- 3. eliminate medications likely to cause hyperkalemia
- 4. sodium polystyrene sulfonate (kayexelate)
-
Define metabolic acidosis.
- pH < 7.35
- pCO2 < 35 mmHg
- serum HCO3- < 24mEq/L
-
Describe the pathophysiology of metabolic acidosis.
- 1. decreased ammonia synthesis
- 2. decreased urinary buffer
- 3. decreased net H+ excretion
- 4. positive H+ balance
- 5. decreased pH
-
Presentation of metabolic acidosis.
- 1. fatigue
- 2. decreased exercise tolerance
- 3. hyperkalemia
-
What are the goals for metabolic acidosis?
- 1. normalize pH
- 2. maintain serum HCO3- within normal range of 22-28 mEq/L
- 3. prevent complications of severe acidosis (bone disease, decreased cardiac contractility)
-
What are the treatment "guidelines" for metabolic acidosis?
- 1. asymptomatic patients with mild acidosis generally do not need emergent treatment
- 2. severe acidosis: pH < 7.2; serum HCO3- < 15 mEq/L
- 3. initial dosing depends on the calculated base deficit
- 4. maintenance doses usually 12-20 mEq/day
- 5. dialysis patients: adjust dialysate fluid
-
What are the treatment options for metabolic acidosis and what are the mechanisms of action?
- 1. sodium bicarbonate
- 2. sodium citrate
- 3. potassium citrate
- MOA: alkalinizing agents
-
What are the side effects of sodium bicarbonate in the treatment of metabolic acidosis?
- GI distress
- hypokalemia
- edema
-
What are the side effects of sodium citrate (Bicitra) in the treatment of metabolic acidosis?
-
What are the side effects of potassium citrate (Polycitra) in the treatment of metabolic acidosis?
- hyperkalemia
- hypernatremia
- cardiac arrhythmias
-
What are the contributing factors of anemia of CKD?
- decreased EPO production
- uremic toxins decrease the life span of RBC
- iron deficiency
- blood loss from HD and lab testing
- poor nutrition (dec. folic acid and B vitamins)
-
What should be evaluated in a CKD patient suspected of having anemia?
- RBC indices
- Iron indices
- Serum ferritin
- Serum iron
- Folic acid and vitamin B12
-
What are the RBC indices that need to be evaluated in a CKD patient with anemia?
-
Why is hematocrit not a good indicator for anemia?
- Because hematocrit fluctuates with volume status
- dehydration = elevated hematocrit
-
What is iron indices?
- Transferrin saturation (Tsat)
- Tsat = serum iron/TIBC x 100
- how much iron is immediately available
-
What is serum ferritin?
- acute phase reactant
- can be elevated in inflammation processes
- not always the best indicator
-
What are the goals for a CKD patient with anemia?
- Increase oxygenation
- Improve QOL
- Prevent complications
-
What is the target hemoglobin for CKD patient?
11-12 g/dL
-
What are the target iron indices for hemodialysis dependent patients?
- Serum ferritin >200 ng/mL AND
- Tsat >20% or content of hemoglobin in reticulocytes (CHr) >29 pg/cell
-
What are the target iron indices for non-hemodialysis or peritoneal dialysis dependent patients?
- Serum ferritin >100 ng/mL AND
- Tsat >20%
-
What is the oral treatment for anemia in CKD patients?
200mg of elemental iron per day
-
How much iron is absorbed in the body and where is it absorbed?
~10% is absorbed in the duodenum and upper jejunum
-
How should oral iron supplements be taken?
- Take on an empty stomach
- Decreased absorption with food
-
How much elemental iron is found in ferrous sulfate?
20%
-
How much elemental iron is found in ferrous sulfate exsiccated? What does exsiccated mean?
- 30%
- Exsiccated = moisture has been removed
-
How much elemental iron is found in ferrous fumarate?
33%
-
How much elemental iron is found in ferrous gluconate?
12%
-
How much elemental iron is found in iron polysaccharide complex (capsule) (a/k/a Niferex -150)?
100%
-
How much elemental iron is found in Heme iron polypeptide (a/k/a Proferrin-ES 12mg)?
100%
-
What are the adverse effects of oral iron supplementation?
- constipation
- nausea
- abdominal cramping
-
What drug interactions are common with oral iron supplementation?
- Vitamin C (ascorbic acid): increases acidity in the stomach which increases the absorption of iron
- Fluoroquinolones: separate from FQ
-
What is the typical IV iron supplementation dose?
Generally give 1 gram in divided doses via dialysis or slow IV infusion
-
Which IV iron supplement has a black box warning and requires a test dose?
Iron dextran (anaphylaxis)
-
What are some common adverse reactions of IV iron supplementation?
Infusion reactions: hypotension, arthralgias, myalgias, fever, flushing, headache, risk of iron overload
-
What is the MOA of erythropoiesis stimulating agents (ESA)?
same biologic activity as endogenous erythropoietin
-
When should erythropoiesis stimulating agents be initated in HD-CKD patients?
- Hgb < 10 g/dL
- Reduce or interrupt dose of ESA if Hgb approaches or exceeds 11g/dL
-
When should erythropoiesis stimulating agents be initated in non-HD-CKD patients?
- Consider when Hgb < 10 g/dL AND the following considerations apply:
- - Rate of Hgb decrease indicated likely need for transfusion AND
- - Reducing risk of alloimmunization and/or other transfusion related risks is a goal
- Reduce or interrupt dose of ESA if Hgb exceeds 10 g/dL
-
What are the boxed warnings of ESA products such as Epogen, Procrit, Aranesp and Omontys?
-
Which ESA drug is only approved for patients receiving dialysis?
Omontys (Peginesatide)
-
How should dose adjustments of ESA's be addressed?
- 1. Individualized for each patient
- 2. Dose increases = once every 4 weeks only
- - if Hgb has not increased by >1 g/dL after 4 weeks of therapy then increase by 25%
- 3. Dose reductions = can be more frequent
- - with rapid Hgb rise (>1 g/dL in any 2-wk period) then decrease by 25%
- 4. Inadequate response over 12-week escalation period
- - higher doses not likely to elicit response
- - use lowest dose possible to reduce need for transfusions
- 5. Monitor Hgb at least weekly until stable, then monthly
|
|